Targeting chronic myeloid leukemia stem cells with ERK5 pathway inhibitors

I Tusa, G Cheloni, M Poteti, A Gozzini, X Deng, N S Gray, S Li, P Dello Sbarba, E Rovida

Article ID: 6445
Vol 32, Issue 4S1, 2018
DOI: https://doi.org/10.54517/jbrha6445
Received: 8 September 2018; Accepted: 8 September 2018; Available online: 8 September 2018; Issue release: 8 September 2018

Abstract

Tyrosine kinase inhibitors (TKi) targeting BCR/ABL are very effective for the treatment of Chronic Myeloid Leukemia (CML). However, discontinuation and/or inefficacy on CML leukemia stem cells (LSC) may lead to relapse. To identify new druggable targets alternative to BCR/ABL, we investigated the role of the Extracellular signal-Regulated Kinase 5 (ERK5) pathway in CML LSC maintenance.



References

Supporting Agencies



Copyright (c) 2018 I Tusa, G Cheloni, M Poteti, A Gozzini, X Deng, N S Gray, S Li, P Dello Sbarba, E Rovida




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).